vimarsana.com
Home
Live Updates
Benitec Biopharma Inc.: Benitec Biopharma Releases Second Qu
Benitec Biopharma Inc.: Benitec Biopharma Releases Second Qu
Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic
Related Keywords
California ,
United States ,
Canada ,
France ,
America ,
William Windham ,
Clinical Development Program Overview ,
Benitec Or Company ,
Benitec Biopharma Inc ,
Nasdaq ,
Solebury Strategic Communications ,
Exchange Commission ,
Regulatory Updates For The Clinical Development Program ,
Research Ethics Board ,
Assay Method Development ,
Second Fiscal Quarter ,
Executive Chairman ,
Chief Executive Officer ,
Oculopharyngeal Muscular Dystrophy ,
Development Program Overview ,
Treatment Evaluation ,
Pharyngeal Residue ,
Maximum Constriction ,
Imaging Grade ,
Swallowing Toxicity Scale ,
Pyriform Sinus Residue ,
Residue Ratio Scale ,
Construction Ratio ,
Treatment Study ,
Clinical Development Program ,
Fourth Calendar Quarter ,
Second Calendar Quarter ,
New Drug ,
Clinical Trial Application ,
Third Calendar Quarter ,
Toxicology Study ,
Parallel Assay Method Development ,
Natural History ,
Relations Contact ,
Solebury Strategic ,
Marcel Torney ,
Benitec ,
Iopharma ,
Eleases ,
Second ,
Quarter ,
023 ,
Financial ,
Results ,
Rovides ,
Perational ,
Update ,